PI
CYTK icon

PineBridge Investments’s Cytokinetics CYTK Stock Holding History

PineBridge Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-36,404
Closed -$1.71M – 747
2024
Q4 		$1.71M Buy
36,404
+10,889
+43% +$566K 0.01% 590
2024
Q3 		$1.35M Buy
+25,515
New +$1.42M 0.01% 601
2019
Q4 		– Sell
-10,445
Closed -$119K – 1074
2019
Q3 		$119K Buy
10,445
+3,984
+62% +$50K ﹤0.01% 914
2019
Q2 		$73K Buy
6,461
+504
+8% +$4.86K ﹤0.01% 849
2019
Q1 		$48K Sell
5,957
-2,381
-29% -$17.5K ﹤0.01% 926
2018
Q4 		$53K Buy
+8,338
New +$61.2K ﹤0.01% 957
2017
Q4 		– Sell
-6,261
Closed -$91K – 1065
2017
Q3 		$91K Buy
6,261
+169
+3% +$2.31K ﹤0.01% 963
2017
Q2 		$74K Buy
+6,092
New +$84.7K ﹤0.01% 975

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PineBridge Investments's CYTK Position: Q1 2025 in Review

PineBridge Investments sold out of Cytokinetics (CYTK) in Q1 2025, closing a stake of 36,404 shares — an estimated $1.71M sold.

PineBridge Investments first reported a position in CYTK in Q2 2017 and held it in 8 quarters. The position peaked at $1.71M in Q4 2024. 355 funds tracked by Wall St. Rank hold CYTK as of Q1 2025.

  • PineBridge Investments reported no remaining Cytokinetics position as of Q1 2025 after selling out during the quarter.
  • PineBridge Investments sold 36,404 Cytokinetics shares in Q1 2025, an estimated $1.71M.
  • PineBridge Investments first reported a position in Cytokinetics in Q2 2017 and held it in 8 quarters.
  • PineBridge Investments's Cytokinetics position peaked at $1.71M in Q4 2024.
  • 355 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2025.

Based on PineBridge Investments's 13F filing for Q1 2025, filed 14 May 2025.